Carcinoembryonic Antigen (CEA) Market: Global Industry Size, Growth, Share and Forecast to 2025

Published By: Brisk Insights | Published On: Jun 12, 2017

Key Findings

The Global Carcinoembryonic Antigen (CEA) Market has been projected to grow at the CAGR of 6.3% market during 2017-2025. In 2016, the market has generated the revenue of $1,904.3 million and now it has been expected to reach up to $3,096.7 million in terms of revenue by 2025. The main application of CEA test is to calculate and observe the protein content in the blood and functionally act as a tumor marker. Its wide application is carried out especially in diagnosis of rectum and colon cancer. According to surveillance authorities, the normal level of CEA is expected to be 5 nanograms per milliliter (ng/mL) for adult smokers and less than 2.5ng/ml for adult non-smokers. Moreover, high CEA levels in human body are sometimes result of a few diseases such as COPD, Crohn’s disease, and cirrhosis. Tumor markers for colorectal cancer are used for initial screening of cancer, staging planning & treatment management, and post-surgery also in order to understand the incidence rate of cancer.

 

Market Segment Insights

The global carcinoembryonic antigen (CEA) market is segmented by applications type. Based on application types, this market is categorized into colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, thyroid cancer and other cancers. In year 2016, colorectal cancer application segment was observed as the largest segment due to the rising demand for minimally invasive diagnostic procedures, growing geriatric population base, and mounting sedentary lifestyle in young population. Moreover, high alcohol consumption and lack of physical exercises in working class is expected to assist the global market of CEA tests during the forecast 2017 – 2025.

 

Regional Insights

In year 2017, North America was observed as the leading geographical region in carcinoembryonic antigen (CEA) market due to key drivers such as rising incidence rates of cancers, availability of accessible and sophisticated healthcare infrastructure, high patient awareness aiding the growth of healthcare expenditure. Asia-Pacific CEA market is expected to achieve fastest CAGR throughout the forecast period 2017 to 2025. The major factors assisting the exponential growth of this region are availability of untapped opportunities in cancer diagnosis, incessant improvement in healthcare infrastructure, economic development and rising patient awareness levels related to early diagnosis.

 

Market Competition Assessment:

Key players in the global chronic myeloid leukemia (CML) market are: Quest Diagnostics, F. Hoffman LA Roche, Abbott Laboratories, GenWay Biotech Inc., Correlogic Systems, Inc., and Others.

 

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions


Chapter 2 Executive Summary
2.1 Global Carcinoembryonic Antigen (CEA) Market Portraiture
2.2 Global Carcinoembryonic Antigen (CEA) Market Share, by Application Type, 2016 (US$ Mn)
2.3 Global Carcinoembryonic Antigen (CEA) Market, by Geography, 2016 (Value %)


Chapter 3 Global Carcinoembryonic Antigen (CEA) Market Analysis
3.1 Global Carcinoembryonic Antigen (CEA) Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Mounting cancer incidences have boosted the demand for research and development in cancer diagnosis technology
3.2.1.2 Minimally invasive cancer diagnosis methods are in high demand
3.2.1.3 In developing countries healthcare expenditure is rising and is expected to assist the demand for effective cancer diagnostic techniques
3.2.2 Challenges
3.2.2.1 Early stage cancer diagnosis is still a challenge for CEA method
3.2.2.2 Regulatory environment in cancer diagnosis is stringent and complicated which hinders the market entry of new companies
3.2.3 Opportunities
3.2.3.1 Technological enhancement in the cancer diagnosis and especially for early cancer diagnosis has high potential in the future
3.3 Attractive Investment Proposition
3.4 Market Share Analysis of Key Manufactures in Carcinoembryonic Antigen (CEA) Market


Chapter 4 Global Carcinoembryonic Antigen (CEA) Market Analysis, by Application Type, 2015-2025 ($ Million)
4.1 Introduction
4.2 Ovarian cancer
4.3 Colorectal Cancer
4.4 Pancreatic Cancer
4.5 Lung Cancer
4.6 Breast Cancer
4.7 Thyroid Cancer
4.8 Other Cancers


Chapter 5 Global Carcinoembryonic Antigen (CEA) Market, by Geography, 2015-2025 ($ Million)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin Americ (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)


Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Quest Diagnostics
6.3 F. Hoffman LA Roche
6.4 GenWay Biotech Inc.
6.5 Correlogic Systems, Inc.

NA

NA

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)